Investors

Home / Investors / Press Releases

Press Releases

20Oct

CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting

20Oct

CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis

11Oct

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for MBX-8025 for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

6Oct

CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclinical Model of NASH at the AASLD 2016 Liver Meeting

5Oct

CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis

8Sep

CymaBay Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

9Aug

CymaBay Reports Second Quarter 2016 Financial Results

2Aug

CymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9

7Jul

CymaBay Announces Participation at Cantor Fitzgerald Healthcare Conference on July 12th in New York

31May

CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)

RSS
Show All

Contact Info

  • 7999 Gateway Blvd., Suite 130
    Newark, CA 94560
  • +1 (510) 293-8800
  • +1 (510) 293-9090

Quick Links

Pipeline